Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 16

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 16
---
 its discretionary authority under Listing Rule 5101. The disclosure stated that Nasdaq determined that the Other Listed Company’s issuance ofwarrants containing a zero exercise price option, like the Series B Warrants, raised public
interest concerns because of the substantial dilution to stockholders and disclosed that on April 29, 2025 Nasdaq informed the Other
Listed Company (the “Second April Notice” and together with the First April Notice, the “April Notices”) that
it halted trading in the Other Listed Company’s securities pending the outcome of the Other Listed Company’s appeal before
the Nasdaq Hearings Panel (the “Panel”). According to the Other Listed Company’s public disclosures, at the time of
receipt of the April Notices, the Other Listed Company was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C), which requires the
market value its publicly held shares to equal at least $15 million (the “MVPH Rule”), and its stock was trading at less
than $.01. Although the Company is not subject to the MVPH Rule because it is listed on the Nasdaq Capital Market, Nasdaq could in its
discretion determine that the issuance of Series B Warrants was against public interest, make at delisting determination and if we appealed
such determination, halt trading in our Common Stock pending such appeal. Any delisting determination or suspension of the trading of
our Common Stock by Nasdaq would have material adverse consequences to the value of our Common Stock as described under “Risk Factors--We
may not be able to maintain the listing of our Common Stock on Nasdaq, which could adversely affect our liquidity and the trading volume
and market price of our Common Stock and decrease or eliminate your investment.”

It is likely that the Company will effect a reverse stock split which could have adverse effects on the value and liquidity of our Common Stock.

As described under “Risk Factors--We may not be able to maintain the listing of our Common Stock on Nasdaq, which could adversely affect our liquidity and the trading volume and market price of our Common Stock and decrease or eliminate your investment,” the Company is required to regain compliance
with the Bid Price Rule by August 25, 2025 or be delisted by Nasdaq. In order to regain compliance, it is likely that the Company will
effect a reverse stock split. A majority of the Company’s stockholders have already approved a reverse stock split by the Company
having a ratio ranging from 1:2 to 1:250